Protara Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Protara Therapeutics

11/08/2026 13:18

Protara Therapeutics Inc TARA.OQ reported a quarterly adjusted loss of 36 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -35 cents.  The mean expectation of seven analysts for the quarter was for a loss of 33 cents per share. Wall Street expected results to range from -35 cents to -31 cents per share.
Reported revenue was zero​; analysts expected zero. 
Protara Therapeutics Inc's reported EPS for the quarter was a loss of 36 cents​.
The company reported a quarterly loss of $21.67 million.
Protara Therapeutics Inc shares had risen by 7.6% this quarter and lost 22.9% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 17.4% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" 
Wall Street's median 12-month price target for Protara Therapeutics Inc is $26.50, about 84.5% above its last closing price of $4.11
This summary was machine generated from LSEG data August 11 at 12:18 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-0.33
-0.36
Missed
Mar. 31 2026 
-0.37
-0.31
Beat
Dec. 31 2025 
-0.32
-0.37
Missed
Sep. 30 2025 
-0.38
-0.31
Beat